Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington’s Disease

Neurotherapeutics - United States
doi 10.1007/s13311-019-00726-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington’s Disease

PLoS ONE
Multidisciplinary
2015English

Neurophysiological and Behavioral Effects of Mycotoxin Deoxynivalenol and Fumonisin

African Journal of Microbiology Research
2013English

White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington’s Disease

PLoS ONE
Multidisciplinary
2016English

Ataxic Symptoms in Huntington’s Disease Transgenic Mouse Model Are Alleviated by Chlorzoxazone

Frontiers in Neuroscience
Neuroscience
2020English

Alterations of Calcium Channels in a Mouse Model of Huntington’s Disease and Neuroprotection by Blockage of CaV1 Channels

ASN Neuro
NeuroscienceNeurology
2019English

Early-Onset Behavioral and Synaptic Deficits in a Mouse Model of Alzheimer's Disease

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2006English

Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington’s Disease

Neurotherapeutics
NeurologyPharmacology
2020English

Pathophysiology in the Suprachiasmatic Nucleus in Mouse Models of Huntington’s Disease

Journal of Neuroscience Research
Molecular NeuroscienceCellular
2018English

Erratum: Sepers Et Al., “Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington’s Disease Mouse Model”

Journal of Neuroscience
Neuroscience
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy